Biopharmaceutical industry

(1) Key fields

Binhai New Area will focus on three sectors- modern biopharmaceutical, new chemical pharmaceuticals and modern traditional Chinese medicine. Bioengineering drugs, detection of gene biochips, enzyme preparations, vaccines and in-vitro diagnostic reagents will be the key fields.

The New Area will speed up the integrated development of raw materials and preparations and sharpen its R & D advantages in hormones, antibiotics, vitamins and amino acid. Efforts will also be made to construct the medicine production bases for cardiovascular and cerebrovascular diseases as well as diabetes and cancer. The area will also improve the quality of preparations and efficiency of developing new medicines.  

Binhai will develop new traditional Chinese medicine and technology for the secondary development of TCM, accelerate the development of new preparations for targeted or positioned release drugs, conduct research on modern TCM testing technology and standards, develop Chinese veterinary drugs and keep a leading position in the modernization of TCM in China.

Binhai New Area will expand the industrial cluster of pharmaceutical R & D outsourcing and promote the industry-university-research cooperation in TCM. Efforts will also be made to develop the R & D and manufacturing of high-end digital medical imaging equipment, diagnostic reagents, testing instruments, interventional therapy, minimally invasive surgical instruments and other medical devices.

(2) Goal

Binhai New Area plans to be a state-level biological medicine industrial base. By 2020, the output value of the industry is expected to reach 160 billion yuan ($25.43 billion), accounting for about 4 percent of the New Area’s industries, and the output value of each square kilometer is expected to reach 13 billion yuan.